Navigation Links
Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response

ncers such as prostate cancer."

Evidence of patient-specific immune responses associated with non patient- specific GVAX immunotherapy products has also been reported in other cancers. In August 2004, the company reported on data published in the Journal of Experimental Medicine from a Phase 1 clinical trial of GVAX immunotherapy for pancreatic cancer that provided evidence that patient-specific immune responses can be generated following treatment with this non patient-specific product. The article described detailed analyses of the immune response to the immunotherapy in three out of 14 patients who were long-term survivors and who also demonstrated strong T cell responses to mesothelin, a tumor- associated protein found in the majority of pancreatic cancers and in the GVAX immunotherapy for pancreatic cancer cells. The specificity of the T cell response to mesothelin was shown to be unique to each responding patient providing further scientific proof-of-concept for the company's GVAX immunotherapy strategy.

GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Cerege
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:10/22/2014)... Calif. , Oct 22, 2014 Antigen ... Irvine, California , announced the receipt of ... Business Innovation Research award (SBIR) from the National Institute of Dental ... fund the development of a Pan-HIV Protein Microarray Chip, ... HIV-1 and HIV-2 subtypes and aid in the development ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
(Date:10/22/2014)... DIEGO , Oct. 21, 2014   ... today the latest genomics research centers to purchase ... Salk Institute, the National Cancer Institute (NCI), NIH ... Sequencing Center). Before Irys, obtaining a comprehensive view ... next generation sequencing (NGS) does not deliver the ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... Inc. (Nasdaq: NUVA ), a medical device company ... for the spine, announced today that Kevin O,Boyle, Chief ... the Oppenheimer 20th Annual Healthcare Conference at The Waldorf ... November 3, 2009. , A live webcast of the ...
... your stomach, relieve your wallet , YONKERS, N.Y., Oct. ... us may suffer from occasional heartburn, a new Best Buy Drugs ... don,t need an expensive drug like Nexium, the "purple pill," for ... to identify "Best Buys" based on safety, effectiveness, and price for ...
Cached Medicine Technology:NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 2NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 3Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Cheap Hosting USA is among the most distinguished review ... that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best cheap ... , “iPower is one of the most reliable hosting ... of useful products for new and old clients. What’s ... and a number of features which will appeal to ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... length ratio (2D:4D) is a trait known for its ... fourth digits; in women, these fingers tend to be ... intriguing hormonal connections, including higher prenatal testosterone levels, lower ... this ratio has also been linked to athletic and ...
... 2, 2008) Athanasios Zavras began receiving messages from ... osteoporosis meds to bone death in the jaw. A ... taking these drugs to postpone dental work, fearing that ... Thats when Zavras, an associate professor in the Harvard ...
... Adverse drug events are more common in older adults ... differently by these drugs than their younger counterparts. A ... clinicians, published in American Family Physician, summarizes steps that ... overuse, misuse, and underuse of medication in older adults. ...
... testosterone levels who received testosterone supplementation increased lean body mass ... no improvement in mobility or cognition compared with men who ... the January 2 issue of JAMA. , Male aging ... levels of testosterone, occurring to a greater extent in some ...
... Catathrenia, or sleep related groaning, is an uncommon ... successfully treated with continuous positive airway pressure (CPAP), according ... of the journal SLEEP. , The study, authored by ... consecutive female patients between the ages of 20 and ...
... Forest University Baptist Medical Center suggests that a three-drug ... glioblastoma multiforme (GBM), a type of brain tumor with ... been developed, and the team is working on the ... cells and spare healthy brain., Waldemar Debinski, M.D., Ph.D., ...
Cached Medicine News:Health News:The risk of osteoarthritis and index to ring finger length ratio 2Health News:The risk of osteoarthritis and index to ring finger length ratio 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2Health News:Tips to prevent adverse drug events in older adults 2Health News:Tips to prevent adverse drug events in older adults 3Health News:Testosterone supplementation for older men appears to have limited benefit 2Health News:New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 2Health News:New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 3Health News:Research suggests new treatment suitable for all patients 2Health News:Research suggests new treatment suitable for all patients 3
System, English (Continental cord), 230 VAC....
Micro-mini fiber optic light....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
The 300W effective dual light source has quality xenon performance....
Medicine Products: